Making a move into complement-mediated rare diseases, Novo Nordisk has entered into a definitive asset purchase and licensing agreement with Omeros for its clinical stage MASP-3-inhibitor humanised monoclonal antibody, zaltenibart (OMS906). Through the deal, which includes US$340 M in upfront and near-term milestone payments, Novo gains exclusive global rights to develop and commercialise zaltenibart for the treatment of complement-mediated blood and kidney disorders such as paroxysmal nocturnal haemoglobinuria (PNH). This partnership strengthens Novo’s rare disease strategy and highlights rising global interest in complement-mediated therapeutic conditions.